

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 711A
Serial No. : ~~Not Yet Known~~ 10/811,170
Applicant: : Mark W. Sleeman et al.
Date Filed : Concurrently Herewith
For : Methods for Treating Diabetes by
Blocking VEGF-Mediated Activity
Examiner : ~~Not Yet Known~~ Jon M. Lockard
Group Art Unit : ~~Not Yet Known~~ 1647

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation</u> <u>Yes</u> <u>No</u>
_____	_____	_____	_____	_____	_____

OTHER DOCUMENTS

Examiner
Initials

mc

De Vriese, A., et al., 2001, "Antibodies Against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experiment Diabetes", J. Am. Soc. Nephrol. 12:993-1000.

—

Ereemina, V., et al., 2003, "Glomerular-Specific Alterations of VEGF-A Expression Lead to Distinct Congenital and Acquired Renal Diseases", J. Clin. Invest. 111:707-716.

—

Cooper, M., et al., 1999, "Increased Renal Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor VEGFR-2 in Experimental Diabetes", Diabetes, 48:2229-2239.

mc

Flyvbjerg, A., et al., 2002, "Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody", Diabetes, 51:3090-3094.

EXAMINER
CONSIDERED

DATE

Don M. F. L.


10/26/05

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

FORM PTO-1449



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Atty Docket No. : REG 711A
 Serial No. : 10/811,170
 Applicant: : Mark W. Sleeman et al.
 Date Filed : March 26, 2004
 Examiner : ~~to be assigned~~ *Jon M. Lockard*
 Group Art Unit : ~~1635~~ *1647*

Commissioner of Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
<i>pmc</i>	WO 00/75319A	14 Dec. 2000	PCT		
<i>pmc</i>	WO 02/060489A	8 Aug. 2002	PCT		

OTHER DOCUMENTS

Examiner Initials	Document
<i>pmc</i>	US Patent Application Publication US 2003/0017977 A1, Xia et al. (Jan. 23, 2003).

Jon M. Lockard

10/26/05

EXAMINER
CONSIDERED

DATE




10/26/05

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:


Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400